3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Vascular Diseases
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pathologic Processes
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphoid Interstitial Pneumonia
1
Lymphatic Diseases
1
Lung Neoplasms
1
Lung Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Lip Neoplasms
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Interventions
Cyclophosphamide
282
Rituximab
260
Etoposide
161
Filgrastim
155
Vincristine
145
Doxorubicin
134
Prednisone
117
Cytarabine
108
Radiotherapy
102
Peripheral Blood Stem Cell Transplantation
90
Methotrexate
90
fludarabine phosphate
87
Melphalan
78
Busulfan
71
Dexamethasone
59
Granulocyte Colony-Stimulating Factor
56
Carmustine
53
fludarabine
51
Bortezomib
46
Tacrolimus
44
Mycophenolic Acid
41
Antilymphocyte Serum
41
Ifosfamide
40
Leucovorin
39
Gemcitabine
38
Whole-Body Irradiation
36
Cyclosporine
35
Bendamustine Hydrochloride
34
sargramostim
33
Methylprednisolone
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled